GitHub28d
yosys – Yosys Open SYnthesis Suite
This is a framework for RTL synthesis tools. It currently has extensive Verilog-2005 support and provides a basic set of synthesis algorithms for various application domains. Yosys can be adapted to ...
National Institute for Health and Care Excellence1mon
In development: Guidance, quality standards and advice
[ID6287] Technology appraisal guidance TBC Sparsentan for treating primary IgA nephropathy [ID6308] Technology appraisal guidance 30 April 2025 Spartalizumab with dabrafenib and trametinib for ...
Taiwan News1mon
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
The two-year results from the study were published in the New England Journal of Medicine and showed that sparsentan delivered clinically meaningful benefit at 108 weeks with significant proteinuria ...
Finanznachrichten1mon
Travere Therapeutics, Inc.: Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGS
The two-year results from the study were published in the New England Journal of Medicine and showed that sparsentan delivered clinically meaningful benefit at 108 weeks with significant ...
Pharmabiz1mon
Renalys Pharma completes patient enrollment in registrational phase III trial of sparsentan for IgA nephropathy in Japan
Renalys Pharma, Inc., a privately held late-stage clinical biopharmaceutical company based in Japan, announced that it has completed patient enrollment and reached the target number of cases for its ...
Malaysian Reserve1y
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
ST. GALLEN, Switzerland, Feb. 23, 2024 /PRNewswire/ — CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval ...